Lung CancerNCT06133816
Lung Cancer Screening Eligibility Assessment
A study testing Framed Introductory Message A, Framed Introductory Message B and Framed Introductory Message C in people with Lung Cancer, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
Trial summary
The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). Read more about this study
- Who is it for?
- Ages 50 to 80 years
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Framed Introductory Message A, Framed Introductory Message B and Framed Introductory Message C
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6,125 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Jul 2023to 31 Jan 2024
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- meet age eligibility (50-80 years old) for LCS based on 2021 USPSTF guidelines; and
- have completed at least one primary care visit at Penn Medicine in 2020-2025
Who cannot join
- have a documented history of lung cancer;
- have a documented history of completing LCS at Penn Medicine;
- are listed as not wanting to be contacted or solicited for research; or
- do not otherwise meet inclusion criteria.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
About this study
Official title: Using a Simplified Tool to Predict Lung Cancer Screening (LCS) Eligibility: Experiment to Test Effects of Messaging on Response Rates
The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.
Read the detailed description
Despite growing evidence that lung cancer screening (LCS) reduces lung cancer-specific mortality, LCS across the United States is remarkably low. This is due in part to challenges with identifying adults who meet eligibility criteria for lifetime smoking intensity (i.e., 20 pack-years or greater), which is often missing from the electronic medical record. We have developed a simplified eligibility tool that has shown accuracy in estimating pack-years. But given the potential for low response rates, there is a great need to identify effective strategies to increasing response rates equitably prior to using it in practice or in future studies. The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help to identify the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.
- Conditions
- Lung Cancer
- Being tested
- Framed Introductory Message A, Framed Introductory Message B, Framed Introductory Message C, Framed Tobacco Use Message A, Framed Tobacco Use Message B
- Keywords
- Lung Cancer Screening
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Framed Introductory Message ABehavioural
Randomly assign patients to receive introductory message encouraging them to complete the survey (version A).
Framed Introductory Message BBehavioural
Randomly assign patients to receive introductory message encouraging them to complete the survey (version B).
Framed Introductory Message CBehavioural
Randomly assign patients to receive introductory message encouraging them to complete the survey (version C).
Framed Tobacco Use Message ABehavioural
Randomly assign patients to receive norming message related to tobacco use (version A).
Framed Tobacco Use Message BBehavioural
Randomly assign patients to receive norming message related to tobacco use (version B).
Financial IncentiveBehavioural
Randomly assigned patients to be entered into a drawing to receive a $100 gift card.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive) | Experimental | Participants will receive two framed messages (AA) plus an incentive Receives: Behavioral: Framed Introductory Message A; Behavioral: Framed Tobacco Use Message A; Behavioral: Financial Incentive |
| Arm 2 (Introductory Message A + Tobacco Use Message A) | Experimental | Participants will receive two framed messages (AA) Receives: Behavioral: Framed Introductory Message A; Behavioral: Framed Tobacco Use Message A |
| Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive) | Experimental | Participants will receive two framed messages (AB) plus an incentive Receives: Behavioral: Framed Introductory Message A; Behavioral: Framed Tobacco Use Message B; Behavioral: Financial Incentive |
| Arm 4 (Introductory Message A + Tobacco Use Message B) | Experimental | Participants will receive two framed messages (AB) Receives: Behavioral: Framed Introductory Message A; Behavioral: Framed Tobacco Use Message B |
| Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive) | Experimental | Participants will receive two framed messages (BA) plus an incentive Receives: Behavioral: Framed Introductory Message B; Behavioral: Framed Tobacco Use Message A; Behavioral: Financial Incentive |
| Arm 6 (Introductory Message B + Tobacco Use Message A) | Experimental | Participants will receive two framed messages (BA) Receives: Behavioral: Framed Introductory Message B; Behavioral: Framed Tobacco Use Message A |
| Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive) | Experimental | Participants will receive two framed messages (BB) plus an incentive Receives: Behavioral: Framed Introductory Message B; Behavioral: Framed Tobacco Use Message B; Behavioral: Financial Incentive |
| Arm 8 (Introductory Message B + Tobacco Use Message B) | Experimental | Participants will receive two framed messages (BB) Receives: Behavioral: Framed Introductory Message B; Behavioral: Framed Tobacco Use Message B |
| Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive) | Experimental | Participants will receive two framed messages (CA) plus an incentive Receives: Behavioral: Framed Introductory Message C; Behavioral: Framed Tobacco Use Message A; Behavioral: Financial Incentive |
| Arm 10 (Introductory Message C + Tobacco Use Message A) | Experimental | Participants will receive two framed message (CA) Receives: Behavioral: Framed Introductory Message C; Behavioral: Framed Tobacco Use Message A |
| Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive) | Experimental | Participants will receive two framed messages (CB) plus an incentive Receives: Behavioral: Framed Introductory Message C; Behavioral: Framed Tobacco Use Message B; Behavioral: Financial Incentive |
| Arm 12 (Introductory Message C + Tobacco Use Message B) | Experimental | Participants will receive two framed messages (CB) Receives: Behavioral: Framed Introductory Message C; Behavioral: Framed Tobacco Use Message B |
What is being measured
The primary outcome is the main question the study is designed to answer.
Full Survey Completion
The proportion of participants that answers all three survey questions via text message among all those randomized.
Measured: 7 days
Secondary outcomes (1)
Partial Survey Completion
The proportion of participants that answer at least one of three survey questions via text message among all those randomized.
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2023
- Study start31 Jul 2023
- Primary completion31 Jan 2024
- Study completion31 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- We will use a randomized factorial design to test the effects of different types of messaging with or without incentives on response rates to an eligibility survey.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 6,125 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- National Institutes of Health (NIH), National Cancer Institute (NCI)
- Responsible party
- Principal investigator, Katharine Rendle, Abramson Cancer Center at Penn Medicine
- Investigators
- Katharine A Rendle, PhD,MSW,MPH, Principal investigator, University of Pennsylvania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06133816
- Sponsor's protocol ID
- UPCC 16523
- Other IDs
- P50CA271338-02, 853337
- Status last verified
- May 2025
- First submitted
- 18 Oct 2023
- Last updated
- 31 May 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Using a Simplified Tool to Predict Lung Cancer Screening (LCS) Eligibility: Experiment to Test Effects of Messaging on Response Rates
- ClinicalTrials.gov ID
- NCT06133816
- Acronym / sponsor ID
- UPCC 16523
- Conditions
- Lung Cancer
- Keywords
- Lung Cancer Screening
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 6,125 participants (actual)
- Lead sponsor
- Abramson Cancer Center at Penn MedicineUniversity, hospital or other
- Collaborators
- National Institutes of Health (NIH), National Cancer Institute (NCI)
- Study start
- 31 Jul 2023 (actual)
- Primary completion
- 31 Jan 2024 (actual)
- Study completion
- 31 Jan 2024 (actual)
- First posted
- 18 Nov 2023 (actual)
- Results
- Posted 31 May 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.
Detailed description
Despite growing evidence that lung cancer screening (LCS) reduces lung cancer-specific mortality, LCS across the United States is remarkably low. This is due in part to challenges with identifying adults who meet eligibility criteria for lifetime smoking intensity (i.e., 20 pack-years or greater), which is often missing from the electronic medical record. We have developed a simplified eligibility tool that has shown accuracy in estimating pack-years. But given the potential for low response rates, there is a great need to identify effective strategies to increasing response rates equitably prior to using it in practice or in future studies. The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help to identify the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 12
- Model description
- We will use a randomized factorial design to test the effects of different types of messaging with or without incentives on response rates to an eligibility survey.
| Arm | Type | Receives |
|---|---|---|
| Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive) | Experimental | Behavioral: Framed Introductory Message A, Behavioral: Framed Tobacco Use Message A, Behavioral: Financial IncentiveParticipants will receive two framed messages (AA) plus an incentive |
| Arm 2 (Introductory Message A + Tobacco Use Message A) | Experimental | Behavioral: Framed Introductory Message A, Behavioral: Framed Tobacco Use Message AParticipants will receive two framed messages (AA) |
| Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive) | Experimental | Behavioral: Framed Introductory Message A, Behavioral: Framed Tobacco Use Message B, Behavioral: Financial IncentiveParticipants will receive two framed messages (AB) plus an incentive |
| Arm 4 (Introductory Message A + Tobacco Use Message B) | Experimental | Behavioral: Framed Introductory Message A, Behavioral: Framed Tobacco Use Message BParticipants will receive two framed messages (AB) |
| Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive) | Experimental | Behavioral: Framed Introductory Message B, Behavioral: Framed Tobacco Use Message A, Behavioral: Financial IncentiveParticipants will receive two framed messages (BA) plus an incentive |
| Arm 6 (Introductory Message B + Tobacco Use Message A) | Experimental | Behavioral: Framed Introductory Message B, Behavioral: Framed Tobacco Use Message AParticipants will receive two framed messages (BA) |
| Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive) | Experimental | Behavioral: Framed Introductory Message B, Behavioral: Framed Tobacco Use Message B, Behavioral: Financial IncentiveParticipants will receive two framed messages (BB) plus an incentive |
| Arm 8 (Introductory Message B + Tobacco Use Message B) | Experimental | Behavioral: Framed Introductory Message B, Behavioral: Framed Tobacco Use Message BParticipants will receive two framed messages (BB) |
| Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive) | Experimental | Behavioral: Framed Introductory Message C, Behavioral: Framed Tobacco Use Message A, Behavioral: Financial IncentiveParticipants will receive two framed messages (CA) plus an incentive |
| Arm 10 (Introductory Message C + Tobacco Use Message A) | Experimental | Behavioral: Framed Introductory Message C, Behavioral: Framed Tobacco Use Message AParticipants will receive two framed message (CA) |
| Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive) | Experimental | Behavioral: Framed Introductory Message C, Behavioral: Framed Tobacco Use Message B, Behavioral: Financial IncentiveParticipants will receive two framed messages (CB) plus an incentive |
| Arm 12 (Introductory Message C + Tobacco Use Message B) | Experimental | Behavioral: Framed Introductory Message C, Behavioral: Framed Tobacco Use Message BParticipants will receive two framed messages (CB) |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- meet age eligibility (50-80 years old) for LCS based on 2021 USPSTF guidelines; and
- have completed at least one primary care visit at Penn Medicine in 2020-2025
Key exclusion criteria (4 listed)
- have a documented history of lung cancer;
- have a documented history of completing LCS at Penn Medicine;
- are listed as not wanting to be contacted or solicited for research; or
- do not otherwise meet inclusion criteria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Framed Introductory Message ARandomly assign patients to receive introductory message encouraging them to complete the survey (version A). | Behavioural | Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive), Arm 2 (Introductory Message A + Tobacco Use Message A), Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive), Arm 4 (Introductory Message A + Tobacco Use Message B) |
| Framed Introductory Message BRandomly assign patients to receive introductory message encouraging them to complete the survey (version B). | Behavioural | Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive), Arm 6 (Introductory Message B + Tobacco Use Message A), Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive), Arm 8 (Introductory Message B + Tobacco Use Message B) |
| Framed Introductory Message CRandomly assign patients to receive introductory message encouraging them to complete the survey (version C). | Behavioural | Arm 10 (Introductory Message C + Tobacco Use Message A), Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive), Arm 12 (Introductory Message C + Tobacco Use Message B), Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive) |
| Framed Tobacco Use Message ARandomly assign patients to receive norming message related to tobacco use (version A). | Behavioural | Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive), Arm 10 (Introductory Message C + Tobacco Use Message A), Arm 2 (Introductory Message A + Tobacco Use Message A), Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive), Arm 6 (Introductory Message B + Tobacco Use Message A), Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive) |
| Framed Tobacco Use Message BRandomly assign patients to receive norming message related to tobacco use (version B). | Behavioural | Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive), Arm 12 (Introductory Message C + Tobacco Use Message B), Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive), Arm 4 (Introductory Message A + Tobacco Use Message B), Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive), Arm 8 (Introductory Message B + Tobacco Use Message B) |
| Financial IncentiveRandomly assigned patients to be entered into a drawing to receive a $100 gift card. | Behavioural | Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive), Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive), Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive), Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive), Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive), Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive) |
Primary outcome
Full Survey Completion
Time frame: 7 days
The proportion of participants that answers all three survey questions via text message among all those randomized.
1 secondary outcome
Partial Survey Completion
Time frame: 7 days
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 May 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Lung Cancer
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 2/3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Non-small Cell Lung Cancer
Recruiting
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
Acute Lymphatic Leukemia, Lymphoma
RecruitingPhase 1
SW-682 in Advanced Solid Tumors
Advanced Solid Tumor, Mesothelioma, Malignant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Katharine A Rendle, PhD,MSW,MPH principal investigator
University of Pennsylvania
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Framed Introductory Message A, Framed Introductory Message B and Framed Introductory Message C in people with Lung Cancer, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 31 May 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Full Survey Completion (time frame: 7 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2025.